{"id":"https://openalex.org/W2969478339","doi":"https://doi.org/10.1212/wnl.92.15_supplement.p2.8-047","title":"Results of a Phase 1 Dose-Ranging Trial, and Design of a Phase 2 Trial, of K0706, a Novel C-Abl Tyrosine Kinase Inhibitor for Parkinson\u2019s Disease. (P2.8-047)","display_name":"Results of a Phase 1 Dose-Ranging Trial, and Design of a Phase 2 Trial, of K0706, a Novel C-Abl Tyrosine Kinase Inhibitor for Parkinson\u2019s Disease. (P2.8-047)","publication_year":2019,"publication_date":"2019-04-09","ids":{"openalex":"https://openalex.org/W2969478339","doi":"https://doi.org/10.1212/wnl.92.15_supplement.p2.8-047","mag":"2969478339"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.92.15_supplement.p2.8-047","doi":"https://doi.org/10.1212/wnl.92.15_supplement.p2.8-047","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.92.15_supplement.p2.8-047","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018396160","display_name":"Andrew Michael Goldfine","orcid":"https://orcid.org/0000-0003-1962-5564","observed_orcids":["https://orcid.org/0000-0003-1962-5564"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew Goldfine","raw_affiliation_strings":["Sun Pharma Advanced Research Company Princeton NJ United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sun Pharma Advanced Research Company Princeton NJ United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052266819","display_name":"Robert D. Faulkner","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Faulkner","raw_affiliation_strings":["Sun Pharma Advanced Research Company Princeton NJ United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sun Pharma Advanced Research Company Princeton NJ United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110119253","display_name":"S. Vasu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vasu Sadashivam","raw_affiliation_strings":["Sun Pharma Advanced Research Company Princeton NJ United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sun Pharma Advanced Research Company Princeton NJ United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054279699","display_name":"Omid Omidvar","orcid":"https://orcid.org/0000-0003-0011-836X","observed_orcids":["https://orcid.org/0000-0003-0011-836X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Omid Omidvar","raw_affiliation_strings":["Southland Neurologic Institute Long Beach CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Southland Neurologic Institute Long Beach CA United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"John Hill","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138823","display_name":"Avail Clinical Research","ror":"https://ror.org/04sc4fe33","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210138823"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Hill","raw_affiliation_strings":["Avail Clinical Research DeLand FL United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avail Clinical Research DeLand FL United States","institution_ids":["https://openalex.org/I4210138823"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037352917","display_name":"Singaravelu Jagadeesan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102103","display_name":"Wake Research","ror":"https://ror.org/01954vf31","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210102103"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Singaravelu Jagadeesan","raw_affiliation_strings":["Wake Research Associates, LLC Raleigh NC United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wake Research Associates, LLC Raleigh NC United States","institution_ids":["https://openalex.org/I4210102103"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110596097","display_name":"Anil Prakash Sharma","orcid":"https://orcid.org/0009-0006-7532-3738","observed_orcids":["https://orcid.org/0009-0006-7532-3738"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anil Sharma","raw_affiliation_strings":["Asclepes Research Center Panorama City CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Asclepes Research Center Panorama City CA United States","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5057266942","display_name":"Siu\u2010Long Yao","orcid":"https://orcid.org/0000-0003-2748-6840","observed_orcids":["https://orcid.org/0000-0003-2748-6840"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Siu-Long Yao","raw_affiliation_strings":["Sun Pharma Advanced Research Company Princeton NJ United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sun Pharma Advanced Research Company Princeton NJ United States","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.1666,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":{"value":0.77063723,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"92","issue":"15_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10919","display_name":"Deep Brain Stimulation and Movement Disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13991","display_name":"Nuclear Receptors and Signaling","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.843999981880188},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.8029999732971191},{"id":"https://openalex.org/keywords/disease-progression","display_name":"disease progression","score":0.6439999938011169},{"id":"https://openalex.org/keywords/mds-updrs","display_name":"MDS-UPDRS","score":0.8240000009536743},{"id":"https://openalex.org/keywords/dopaminergic-neuron-degeneration","display_name":"dopaminergic neuron loss","score":0.800000011920929},{"id":"https://openalex.org/keywords/alpha-synuclein-aggregation","display_name":"alpha-synuclein aggregation","score":0.8259999752044678},{"id":"https://openalex.org/keywords/early-parkinson-s-disease","display_name":"early-stage Parkinson's disease","score":0.6549999713897705}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5860780477523804},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.5733709335327148},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.5723943710327148},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5215004086494446},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.47029444575309753},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.41809168457984924},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4180545508861542},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.40091472864151},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3997263014316559},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.1886940896511078},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.12158244848251343},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.09291884303092957},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.92.15_supplement.p2.8-047","doi":"https://doi.org/10.1212/wnl.92.15_supplement.p2.8-047","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.92.15_supplement.p2.8-047","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2575392409","https://openalex.org/W2540689820","https://openalex.org/W7130655259","https://openalex.org/W2620877413","https://openalex.org/W4390907947","https://openalex.org/W2901089527","https://openalex.org/W2547383744","https://openalex.org/W7127270529","https://openalex.org/W4406400543","https://openalex.org/W3215211915"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"determine":[2,89,156],"the":[3,18,78,199,261,264],"safety":[4],"and":[5,44,48,64,138,220,241],"efficacy":[6,72,90,161],"of":[7,20,110,132,153,158,178,181,236],"K0706,":[8],"a":[9,26,103,142,148,164,272,300,324,348,372,405,440,475,509],"novel":[10],"c-Abl":[11,50,83,273],"tyrosine":[12,27],"kinase":[13,28],"inhibitor":[14],"(TKI),":[15],"to":[16,33,59,77,88,155,162,176,231,245,259,281],"slow":[17,282],"progression":[19,283],"Parkinson\u2019s":[21,39,92,115,206,287],"disease.":[22,93,116,288],"Background:":[23],"C-Abl":[24,68],"is":[25,271],"that":[29],"has":[30,101,292,316,340,364,385,397,420,432,455,467,489,501],"been":[31,53,209],"hypothesized":[32],"activate":[34],"multiple":[35,56,106],"pathways":[36],"involved":[37],"in":[38,55,73,91,112,135,141,193,248,284,530],"disease":[40,207],"including":[41],"synuclein":[42],"aggregation":[43],"parkin":[45],"deactivation.":[46],"K0706":[47,111,124,133,154,182,211,237,270],"other":[49,306,330,354,378,411,446,481,515],"TKIs":[51,69,84],"have":[52,70,85,208],"shown":[54],"animal":[57,250],"models":[58],"reduce":[60],"dopaminergic":[61],"cell":[62],"death":[63],"improve":[65],"behavioral":[66],"outcomes.":[67],"proven":[71],"treating":[74],"leukemias":[75],"related":[76],"Bcr-Abl":[79],"mutation,":[80],"but":[81],"no":[82,216,221],"completed":[86],"testing":[87],"Design/Methods:":[94],"Sun":[95,309,333,357,390,425,460,494,518],"Pharma":[96,310,334,358,391,426,461,495,519],"Advanced":[97,311,335,359,392,427,462,496,520],"Research":[98,312,336,360,393,428,450,463,485,497,521],"Company":[99],"(SPARC)":[100],"conducted":[102],"phase":[104,149,165,200,265],"1,":[105],"ascending":[107],"dose":[108,240],"trial":[109,152],"subjects":[113,204],"with":[114,123,129,169,205,215,239,254,308,332,356,380,413,448,483,517],"Subjects":[117,168],"were":[118],"treated":[119],"for":[120,160,185,263,278,296,320,344,368,401,436,471,505],"2":[121,266],"weeks":[122],"or":[125,183,226,305,329,353,377,410,445,480,514],"placebo":[126,184],"(3:1":[127],"randomization)":[128],"blood":[130],"levels":[131,140,256],"measured":[134],"all":[136],"subjects,":[137],"CSF":[139,255],"subset.":[143],"SPARC":[144],"will":[145,173,190],"next":[146],"begin":[147],"2,":[150],"multi-center":[151],"proof":[157],"concept":[159],"support":[163,388,423,458,492],"3":[166],"program.":[167],"early":[170,285],"stage":[171,286],"PD":[172,249],"be":[174,191,232,246],"randomized":[175],"one":[177],"two":[179],"doses":[180,262],"9":[186],"months;":[187],"primary":[188],"outcome":[189],"change":[192],"MDS-UPDRS":[194],"Parts":[195],"2+3.":[196],"Results:":[197],"In":[198],"1":[201],"trial,":[202],"46":[203],"studied.":[210],"was":[212],"well":[213],"tolerated":[214],"serious":[217],"adverse":[218,223],"events,":[219,224],"consistent":[222],"laboratory":[225],"vital":[227],"sign":[228],"abnormalities":[229],"deemed":[230],"drug-related.":[233],"Plasma":[234],"concentrations":[235],"increased":[238],"reached":[242],"those":[243],"found":[244],"efficacious":[247],"models;":[251],"they":[252],"along":[253],"are":[257],"used":[258],"choose":[260],"trial.":[267],"Conclusions:":[268],"SPARC\u2019s":[269],"TKI":[274],"currently":[275],"being":[276],"studied":[277],"its":[279],"ability":[280],"Disclosure:":[289],"Dr.":[290,314,338,362,383,395,418,430,453,465,487,499,523],"Goldfine":[291],"received":[293,317,341,365,386,398,421,433,456,468,490,502],"personal":[294,318,342,366,399,434,469,503],"compensation":[295,319,343,367,400,435,470,504],"consulting,":[297,321,345,369,402,437,472,506],"serving":[298,322,346,370,403,438,473,507],"on":[299,323,347,371,404,439,474,508],"scientific":[301,325,349,373,406,441,476,510],"advisory":[302,326,350,374,407,442,477,511],"board,":[303,327,351,375,408,443,478,512],"speaking,":[304,328,352,376,409,444,479,513],"activities":[307,331,355,379,412,447,482,516],"Company.":[313,337,361,394,429,464,498,522],"Faulkner":[315],"Sadashivam":[339],"Omidvar":[363,384],"Southland":[381],"Neurologic.":[382],"research":[387,422,457,491],"from":[389,424,459,493],"Hill":[396,419],"Avail":[414],"Clinical":[415],"Research,":[416],"LLC.":[417,452],"Jagadeesan":[431,454],"Wake":[449],"Associates,":[451],"Sharma":[466,488],"Asclepes":[484],"Center.":[486],"Yao":[500,524],"holds":[525],"stock":[526,528],"and/or":[527],"options":[529],"Merck.":[531]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2019-08-29T00:00:00"}